We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AdComm Backs Celltrion’s Remicade Biosimilar 21-3
An FDA advisory committee gave Celltrion’s biosimilar candidate for Remicade a strong show of support in February, backing its approval for six different indications.